Table 4. Incremental cost-effectiveness ratios for the MMS vs control and USS vs control comparisons within the trial period (ROCA=£20).
|
Multimodal
vs
control |
Ultrasound
vs
control |
|||||
|---|---|---|---|---|---|---|
| Cost difference | Effect difference | ICER (95% confidence interval) | Cost difference | Effect difference | ICER (95% confidence interval) | |
| Discounted at 1.5% and both costs and effects adjusted for censoring | £256 | 0.0028 | £91 452 per LYG (£90 909, £92 001) | £1208 | 0.00193 | £625 801 per LYG (£620 451, £631 245) |
| Discounted at 3.5% and both costs and effects adjusted for censoring | £239 | 0.00224 | £106 497 per LYG (£105 840, £107 162) | £1137 | 0.00152 | £748 315 per LYG (£741 446, £755 312) |
|
Results for multimodal
vs
control ICER extrapolated to 25 years | ||||||
| Discounted at 1.5% | £427 | 0.01421 | £30 033 per LYG | |||
| Discounted at 3.5% | £358 | 0.01008 | £35 544 per LYG | |||
Abbreviations: ICER=incremental cost-effectiveness ratio; LYG=life year gained; MMS=multimodal screening; ROCA=risk of ovarian cancer algorithm; USS=ultrasound screening. Note: ICER values differ from straight division of cost difference by effect difference due to rounding.